MGMT and neoplasm: Predictive biomarkers, such as MGMT promoter methylation, specifically help determine whether a patient will benefit from a targeted or cytotoxic therapy; in the case of MGMT, methylation silences the DNA repair enzyme, thus making tumor cells more susceptible to alkylating agents like temozolomide [38].